Compare nVent Electric (NVT) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
nVent Electric vs Spyre Therapeutics Inc. Common Stock — how do they compare? nVent Electric trades at $150.99 (market cap $26.14B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: nVent Electric is far larger — about 3.5× Spyre Therapeutics Inc. Common Stock's market cap, and nVent Electric pays a 0.52% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold nVent Electric for 14 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| NVT | SYRE | |
|---|---|---|
Market Cap | $26.14B | $7.52B |
Volume | 1,878,946 | 1,441,031 |
Sector | Industrials | Health |
52-Week High | $184.34 | $108.92 |
52-Week Low | $94.99 | $22.18 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | $27.51B | $6.52B |
Dividend Yield | 0.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVT trades at $161.47, down 0.8% with a bullish technical outlook and strong institutional support. The company demonstrates robust earnings momentum with three consecutive quarterly beats and a 61% YTD surge driven by AI data-center demand. Recent developments include the $1.75 billion acquisition of Maverick Power and a strategic collaboration with AMD on cooling solutions for AI infrastructure, positioning NVT for continued growth in the expanding data center market.
While NVT's premium valuation (P/E 44.85) and rising competition present risks, strong analyst consensus (85% buy rating) with a $203.86 price target suggests 26% upside potential. The company's expanding AI infrastructure portfolio and solid cash flow generation support long-term growth, though investors should monitor tariff impacts and valuation compression risks in a competitive landscape.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About nVent Electric
nVent provides electrical connection and protection solutions, including enclosures, fastening systems, and thermal management products. Its products help support electrical and industrial infrastructure across multiple end markets.
Read more on NVT →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
